Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Clancy

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 30, 2020
Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal AdenocarcinomaChunxia Du, Annacarolina da Silva, Vicente Morales-Oyarvide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Rachel B Keller, Kevin S Kapner, et al.
British Journal of Cancer|October 6, 2017
Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survivalVicente Morales-Oyarvide, Douglas A Rubinson, Richard F Dunne, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Nature Biotechnology|April 23, 2014
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancerJens G Lohr, Viktor A Adalsteinsson, Kristian Cibulskis, et al.
Gut|December 20, 2023
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancerRoni Ben-Ami, Qiao-Li Wang, Jinming Zhang, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 3, 2018
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancerMatthew B Yurgelun, Anu B Chittenden, Vicente Morales-Oyarvide, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
JAMA Oncology|November 4, 2017
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal AdenocarcinomaZhi Rong Qian, Douglas A Rubinson, Jonathan A Nowak, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 30, 2020
Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal AdenocarcinomaChunxia Du, Annacarolina da Silva, Vicente Morales-Oyarvide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Rachel B Keller, Kevin S Kapner, et al.
British Journal of Cancer|October 6, 2017
Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survivalVicente Morales-Oyarvide, Douglas A Rubinson, Richard F Dunne, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
Nature Biotechnology|April 23, 2014
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancerJens G Lohr, Viktor A Adalsteinsson, Kristian Cibulskis, et al.
Gut|December 20, 2023
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancerRoni Ben-Ami, Qiao-Li Wang, Jinming Zhang, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 3, 2018
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancerMatthew B Yurgelun, Anu B Chittenden, Vicente Morales-Oyarvide, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
JAMA Oncology|November 4, 2017
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal AdenocarcinomaZhi Rong Qian, Douglas A Rubinson, Jonathan A Nowak, et al.
Pageof 9